# US 2026/0062413 A1 · Kinase inhibitors for the treatment of neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062413 A1
- Document ID: US20260062413A1
- Status: Published application
- Kind: A1
- Application number: 19/321,360
- Filed: 2025-09-08
- Published: 2026-03-05
- Earliest claimed: 2019-09-11
- Assignees: Ohio State Innovation Foundation; Reaction Biology Corporation
- Applicants: Ohio State Innovation Foundation; Reaction Biology Corporation
- Inventors: Yangbo Feng; Sung Ok Yoon
- Web page: https://patentgrep.com/patent/US20260062413A1

## CPC

- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are compounds that are kinase inhibitors. The compounds have improved properties that lead to specific targeting of kinases without inhibiting the activity of related enzymes, which make them useful for therapeutic intervention in a variety of disorders and disease in which inhibition of the kinase can be clinically useful, e.g., Alzheimer's disease and other neurodegenerative diseases. The compounds can also be used in methods of treating a neurodegenerative disease associated with inflammation, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, epilepsy, stroke, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), or a disease or disorder such as deafness, glaucoma, organ failure, or cancers, including, but not limited to, those susceptible to combination therapy with epigenetic targets such as those associated with bromodomain (BRD) proteins, histone deacetylases (HDACs), and the like.

## Claims

### Claim 1

A compound having a structure represented by a formula:
wherein each of R1a and R1b are independently selected from hydrogen, C1-C8 nitrile, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 haloalkyl, C3-C8 cycloalkyl, C3-C8 heterocyclyl, heteroaryl, and aryl;
wherein each of R2a, R2b, R2c, R2d, and R2e are independently selected from hydrogen, halo, hydroxy, nitro, azido, —SF5, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 aminoalkyl, C1-C3 hydroxyalkyl, and —(C0-C3 alkanediyl)-NR5aR5b;
wherein each occurrence of R5a and R5b is independently selected from hydrogen, C1-C3 alkyl, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, aryl and heteroaryl;
wherein A is a structure represented by a formula:
wherein each of R3a and R3b is selected from hydrogen, halo, hydroxy, nitro, amino, azido, —SF5, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 aminoalkyl, and C1-C3 hydroxyalkyl;
wherein Q1 is N or CR4a;
wherein Q2 is N or CR4b;
wherein Q3 is N or CR4c;
wherein each of R4a, R4b, and R4c, when present, is independently selected from hydrogen, halo, hydroxy, nitro, azido, —SF5, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 aminoalkyl, C1-C3 hydroxyalkyl, and —(C0-C3 alkanediyl)-NR5aR5b;
wherein Z is selected from —O—, —S—, —NR6—, —S(O)—, and —S(O)2—,
wherein R6 is selected from hydrogen and C1-C3 alkyl;
or a pharmaceutically acceptable salt or derivative thereof.

### Claim 2 (depends on 1)

The compound of claim 1, having a structure represented by a formula:

### Claim 3 (depends on 2)

The compound of claim 2, having a structure represented by a formula:
wherein Z is selected from —O— and —NH—.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R2b, R2c, and R2d are hydrogen, and R2a is halo and R2e is hydrogen.

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 4)

The compound of claim 4, wherein R2a is halo or alkoxy and R2e is hydrogen, and R2b is alkoxy.

### Claim at position 7

9-14. (canceled)

### Claim 15 (depends on 4)

The compound of claim 4, wherein R2e is selected from halo and alkoxy.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 4)

The compound of claim 4, wherein R1b is selected from C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, C3-C8 heterocyclyl, and heteroaryl.

### Claim at position 12

19-23. (canceled)

### Claim 24 (depends on 4)

The compound of claim 4, wherein R4a and R4c are hydrogen and R4b is selected from halo and C1-C8 alkoxy.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 4)

The compound of claim 4, wherein Z is —O— or —NH—.

### Claim 28

(canceled)

### Claim 29 (depends on 2)

The compound of claim 2, having a structure represented by a formula:
wherein Z is selected from —O— and —NH—.

### Claim 30 (depends on 29)

The compound of claim 29, wherein R2b, R2c, and R2d are hydrogen.

### Claim 31 (depends on 30)

The compound of claim 30, wherein R2a is halo and R2e is hydrogen or alkoxy, or R2a and R2e are halo.

### Claim at position 21

32-37. (canceled)

### Claim 38 (depends on 30)

The compound of any of claim 30, wherein R1b is selected from C1-C8 alkyl, C1-C8 alkoxy, C3-C8 heterocyclyl, and heteroaryl.

### Claim at position 23

39-43. (canceled)

### Claim 44 (depends on 2)

The compound of claim 2, having a structure represented by a formula:
wherein Z is selected from —O— and —NH—.

### Claim 45 (depends on 44)

The compound of claim 44, wherein R2b, R2c, R2d, and R2e are hydrogen and R2a is halo.

### Claim at position 26

46-50. (canceled)

### Claim 51 (depends on 44)

The compound of claim 44, wherein R1b is selected from C1-C8 alkyl, C1-C8 alkoxy, C3-C8 heterocyclyl, and heteroaryl.

### Claim at position 28

52-55. (canceled)

### Claim 56 (depends on 2)

The compound of claim 2, having a structure represented by a formula:
wherein Z is selected from —O—, —NH—, and —NCH3—.

### Claim 57 (depends on 56)

The compound of claim 56, wherein R2a is selected from halo and alkoxy.

### Claim 58

(canceled)

### Claim 59 (depends on 57)

The compound of claim 57 wherein R2b, R2c, R2d, and R2 are hydrogen or R2b is selected from halo and alkoxy and R2c, R2d, and R2e are hydrogen.

### Claim at position 33

60-62. (canceled)

### Claim 63 (depends on 57)

The compound of claim 57 wherein R2c is halo and R2b, R2d, and R2e are hydrogen: R2d is halo and R2b, R2c, and R2 are hydrogen: wherein g is halo and R2b, R2c, and R2d are hydrogen: R2e is halo and R2b, R2c, and R2d are hydrogen; or R2e is halo and R2b, R2c, and R2d are hydrogen.

### Claim at position 35

64-69. (canceled)

### Claim 70 (depends on 57)

The compound of claim 57, wherein R1b is selected from C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 alkoxy, C3-C8 heterocyclyl, and heteroaryl.

### Claim at position 37

71-74. (canceled)

### Claim 75 (depends on 57)

The compound of claim 57, wherein R3b is selected from C1-C8 alkyl and hydrogen.

### Claim 76

(canceled)

### Claim 77 (depends on 57)

The compound of claim 57, wherein R4b is selected from C1-C8 alkyl and hydrogen.

### Claim at position 41

78-92. (canceled)

### Claim 93 (depends on 1)

The compound of claim 1, having a structure represented by a formula:

### Claim 94 (depends on 93)

The compound of claim 93, wherein R1a is hydrogen.

### Claim 95 (depends on 93)

The compound of claim 93, wherein R1b is selected from C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 heterocyclyl, heteroaryl, and C1-C8 alkoxy.

### Claim 96 (depends on 93)

The compound of claim 93, wherein R3a and R3b are independently hydrogen or methyl.

### Claim 97 (depends on 93)

The compound of claim 93, wherein Z is selected from —O—, —NH—, and —NCH3—.

### Claim 98 (depends on 93)

The compound of claim 93, wherein Q1, Q2, and Q3 are —CH; Q1 and Q3 are —CH and Q2 is N; Q1 and Q2 are —CH and Q3 is N; Q1 is N and Q2 and Q3 are —CH; or Q1 is —CH and Q2 and Q3 are N.

### Claim at position 48

99-102. (canceled)

### Claim 103 (depends on 93)

The compound of claim 93, wherein R2a is selected from halo and alkoxy.

### Claim 104

(canceled)

### Claim 105 (depends on 93)

The compound of claim 93 wherein R2b, R2c, R2d, and R2e are hydrogen; R2b is selected from halo and alkoxy and R2c, R2d, and R2 are hydrogen: R2c is halo and R2b, R2d, and R2e are hydrogen; R2d is halo and R2b, R2c, and R2 are hydrogen; or R2e is halo and R2b, R2c, and R2d are hydrogen.

### Claim at position 52

106-115. (canceled)

### Claim 116 (depends on 1)

The compound of claim 1, having a structure represented by a formula:
or combinations thereof.

### Claim 117 (depends on 116)

The compound of claim 116, wherein the compound is a pharmaceutically acceptable salt thereof.

### Claim at position 55

118-136. (canceled)

### Claim 137 (depends on 1)

The compound of claim 1, having a structure represented by a formula:
or combinations thereof.

### Claim 138 (depends on 137)

The compound of claim 137, wherein the compound is a pharmaceutically acceptable salt thereof.

### Claim 139

(canceled)

### Claim 140 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of any of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 141 (depends on 1)

A method for the treatment of a disease or disorder in a mammal comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of any of claim 1.

### Claim at position 61

142-160. (canceled)

### Claim 161 (depends on 1)

A method for inhibiting c-Jun N-terminal kinase 3 (JNK3) activity in at least one cell, comprising the step of contacting the at least one cell with an effective amount of at least one compound of any of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 63

162-172. (canceled)

### Claim 173 (depends on 1)

A kit comprising a therapeutically effective amount of at least one compound of any of claim 1, or a pharmaceutically acceptable salt thereof, and:
a. at least one agent known to treat a disease or disorder of the central nervous system, a disease or disorder of the peripheral nervous system, organ failure, or a cancer; and
b. instructions for treating a disease or disorder of the central nervous system, a disease or disorder of the peripheral nervous system, organ failure, or a cancer.

### Claim at position 65

174-191. (canceled)
